Elsevier

Bone

Volume 66, September 2014, Pages 240-250
Bone

Original Full Length Article
Modifying the osteoblastic niche with zoledronic acid in vivo—Potential implications for breast cancer bone metastasis

https://doi.org/10.1016/j.bone.2014.06.023Get rights and content
Under a Creative Commons license
open access

Highlights

  • A single, clinically relevant, dose of zoledronic acid rapidly reduces activity and number of both osteoblasts and osteoclasts in vivo.

  • This is accompanied by significant increased extra-cellular matrix content in areas of the metaphysis comprising the bone metastatic niche.

  • Breast cancer cells appear to preferentially home to osteoblast- and extra-cellular matrix rich regions of the metaphysis.

  • Osteoblasts are suggested to be a key component of the bone metastatic niche.

Abstract

Introduction

Bone metastasis is the most common complication of advanced breast cancer. The associated cancer-induced bone disease is treated with bone-sparing agents like zoledronic acid. Clinical trials have shown that zoledronic acid also reduces breast cancer recurrence in bone; potentially by modifying the bone microenvironment surrounding disseminated tumour cells. We have characterised the early effects of zoledronic acid on key cell types of the metastatic niche in vivo, and investigated how these modify the location of breast tumour cells homing to bone.

Methods

Female mice were treated with a single, clinically achievable dose of zoledronic acid (100 μg/kg) or PBS. Bone integrity, osteoclast and osteoblast activity and number/mm trabecular bone on 1, 3, 5 and 10 days after treatment were assessed using μCT, ELISA (TRAP, PINP) and bone histomorphometry, respectively. The effect of zoledronic acid on osteoblasts was validated in genetically engineered mice with GFP-positive osteoblastic cells. The effects on growth plate cartilage were visualised by toluidine blue staining. For tumour studies, mice were injected i.c. with DID-labelled MDA-MB-231-NW1-luc2 breast cancer cells 5 days after zoledronic acid treatment, followed by assessment of tumour cell homing to bone and soft tissues by multiphoton microscopy, flow cytometry and ex vivo cultures.

Results

As early as 3 days after treatment, animals receiving zoledronic acid had significantly increased trabecular bone volume vs. control. This rapid bone effect was reflected in a significant reduction in osteoclast and osteoblast number/mm trabecular bone and reduced bone marker serum levels (day 3–5). These results were confirmed in mice expressing GFP in osteoblastic linage cells. Pre-treatment with zoledronic acid caused accumulation of an extra-cellular matrix in the growth plate associated with a trend towards preferential [1] homing of tumour cells to osteoblast-rich areas of bone, but without affecting the total number of tumour cells. The number of circulating tumour cells was reduced in ZOL treated animals.

Conclusion

A single dose of zoledronic acid caused significant changes in the bone area suggested to contain the metastatic niche. Tumour cells arriving in this modified bone microenvironment appeared to preferentially locate to osteoblast-rich areas, supporting that osteoblasts may be key components of the bone metastasis niche and therefore a potential therapeutic target in breast cancer.

Abbreviations

BP
Bisphosphonate
ECM
Extracellular matrix
GFP
Green fluorescent protein
HSC
Hematopoietic stem cell
NBP
Nitrogen-containing bisphosphonate
PBS
Phosphate buffered saline
ROI
Region of interest
TRAP
Tartrate resistant alkaline phosphatase
PINP
Procollagen type 1N-terminal propeptide
ZOL
Zoledronic acid

Keywords

Metastatic niche
Osteoblast
Osteoclast
Breast cancer
Homing

Cited by (0)